Home / Cancer treatment in China / Colorectal cancer treatment
Biomarker before the drug
Does Immunotherapy Work for Colorectal Cancer?
Checkpoint immunotherapy can be a major option when colorectal cancer is MSI-H or dMMR. That means mismatch repair is not working and the tumor carries many mutations. It is a minority of metastatic cases. MSS or pMMR disease, which is most colorectal cancer, does not get the same result from a checkpoint inhibitor. An investigational combination, including a new bispecific antibody that has only trial permission, is not established routine care. The biomarker comes before the product name.
Applicability: this answer is about checkpoint immunotherapy. A cell therapy, a vaccine, or a bispecific antibody in a trial is a different product and needs its own evidence.
MSI-H / dMMRMSS / pMMRIND is not approval
Read the biomarker before the product
MSI-H means microsatellite instability-high. dMMR means mismatch-repair deficiency. They point to the same biology in this setting: the tumor’s repair system is broken. MSS means microsatellite stable. pMMR means mismatch repair is intact. Most metastatic colorectal cancers are MSS or pMMR.
MSI-H or dMMR
In this group, checkpoint immunotherapy may be a major treatment option, including in metastatic first-line care. Cao and Jiang, in the 1 October 2026 interpretation, say nivolumab alone or with ipilimumab was added as a first-line grade I recommendation in metastatic disease. That sentence does not itself write MSI-H. This page does not extend it to MSS or pMMR cancer, and it does not treat every PD-1 product in China as interchangeable. The same interpretation adds FOLFOX plus atezolizumab as an adjuvant option for stage III dMMR colon cancer, and it separates upfront surgery from neoadjuvant immunotherapy in non-metastatic MSI-H or dMMR colon cancer. Those are guideline sentences, not a product menu.
MSS or pMMR
Checkpoint immunotherapy is not automatically equivalent in MSS or pMMR colorectal cancer. Investigational combinations must not be presented as established routine care. The August 2026 IND for opamtistomig, a PD-L1/4-1BB bispecific antibody, allows a phase Ib/II combination trial in metastatic colorectal cancer. It does not approve a treatment. Details stay on the 2026 evidence page.
Where this sits in the cluster
The decision map is the colorectal cancer treatment page. Access in China is colorectal cancer treatment in China.
In this cluster
- Colorectal cancer treatment
- Treatment by stage
- Metastatic disease
- Immunotherapy (this page)
- New treatments in 2026
- Treatment in China
Technology pages already on this site, used only when a case actually needs them: proton therapy, microwave ablation, cryoablation, and interventional oncology. None of those replaces surgery or systemic therapy for colorectal cancer as a default.
Questions people ask
Does immunotherapy work for colorectal cancer?
It can be a major option for MSI-H or dMMR colorectal cancer. It is not established routine care for the much larger MSS or pMMR group. A trial combination is not the same thing as an approved checkpoint inhibitor.
What is MSI-H or dMMR colorectal cancer?
MSI-H means microsatellite instability-high. dMMR means the mismatch-repair proteins are deficient. In colorectal cancer these findings mark the group in which checkpoint immunotherapy may be a major option. MSS and pMMR are the opposite findings and are not treated with the same assumption.
Sources
- NCI, Colon Cancer Treatment (PDQ) patient version. Used for the general distinction between colon treatment and a personal plan.
- NCI, Rectal Cancer Treatment (PDQ) patient version. Used for the point that rectal cancer more often involves radiation than colon cancer.
- National Health Commission colorectal cancer specification, 2025 edition. English summary: Chin J Cancer Res 2025;37(6):949-961. doi 10.21147/j.issn.1000-9604.2025.06.07. This is a practice framework, not a 2026 drug list.
- CSCO colorectal guideline version 2026, as interpreted in Chin J Cancer Res 2026;38(3):329-335. doi 10.21147/j.issn.1000-9604.2026.03.10. The full guideline PDF was not pasted here.
- Cao and Jiang, 1 October 2026. Digestive Oncology, electronic edition, 2026;18(3):358-363. Used for the metastatic nivolumab sentence, the stage III dMMR adjuvant sentence, and the first-line BRAF move.
- BioPharm International, 3 August 2026, reporting the Leads Biolabs announcement that CDE approved an IND for a phase Ib/II trial of opamtistomig plus other drugs in metastatic colorectal cancer. A separate August 2026 NDA acceptance for the same antibody is for extrapulmonary neuroendocrine carcinoma, not colorectal cancer.
Last reviewed: 3 October 2026. A trial permission, a guideline sentence, and a drug label are three different documents.
Check whether immunotherapy fits this biomarker
MSI-H or dMMR is not the same finding as MSS or pMMR. ParkMega does not read a biomarker report or promise a response.